EPL’s Indovida merger and 30% B&C growth drive optimism

EPL Limited — Q4 FY26 Earnings Conference Call (held May 14, 2026)

1. Overall Tone of Management

Optimistic. Management highlights “landmark quarter” and “transformational move” (proposed merger with Indovida), while also reporting strong operating momentum (“highest ever revenue growth in the last 5 years”, “fourth consecutive quarter of double-digit revenue growth”) and confidence in navigating the Middle East crisis (“We remain confident…”).

2. Key Themes from Management Commentary

• Merger as a strategic inflection
• Proposed merger with Indovida to create a “nearly $1 billion consumer packaging platform” with broader portfolio (rigid + flexible), stronger manufacturing/innovation, and margin/value accretion.

• Emphasis on regulatory approval timeline and maintaining independence until approvals.

• Beauty & Cosmetics (B&C) is the growth engine

• Record B&C growth: “record 30% year-on-year growth” in the quarter; B&C delivered “fourth consecutive quarter of over 20% growth”.

• Management frames B&C as now larger than Oral Care in most key markets, shifting portfolio mix.

• Resilient margins + improving capital efficiency

• EBITDA margin sustained above 20%: “EBITDA margin stood at 20.2%” (Q4) and “margins at 20.4%” (FY).
• Deleveraging: net debt/EBITDA improved to “0.52x”.

• ROCE improved to “19%”.

• Middle East crisis: supply security + cost pass-through

• Crisis impacts “availability and cost of key raw materials”.
• Mitigation: prioritize supply security; “nearly 50%” of business covered by contractual pass-through; model evolved to include “landed cost plus power pass-through”.

• Confidence: “recover all additional costs” with “no lag” expected.

• Growth outlook anchored in guidance discipline

• Reiterates long-term growth guidance: low double-digit revenue growth (11%–13%) and EBITDA growth slightly ahead.

3. Q&A Analysis

Theme A: Cost inflation / pass-through mechanics and margin risk (Middle East crisis)

• Core questions
• How much cost inflation is expected and how FY27 margins will behave?
• Clarify whether pass-through covers raw materials + logistics + power + currency/freight.
• Whether non-contractual customers will lag in price recovery.
• Management response
• Availability secured “till at least… middle of July” and extended weekly.
• Pass-through model: “landed cost plus power pass-through model” (covers multiple cost elements).
• Contractual coverage: “nearly 50%” with agreements; non-contractual: proactive price increases in-market.
• Confidence: “recover all additional costs” and “no lag” even for non-contractual over time.
• Notable signals
• Some precision gaps: management avoids quantifying inflation magnitude (“very difficult to give one number”).
• Strong reassurance language (“very confident”, “no lag”), but without hard numbers.

Theme B: AMESA performance—why EBITDA/EBIT lag despite revenue growth

• Core questions
• AMESA revenue up ~10% but EBITDA growth low (~1%); EBIT down—is it crisis-related or structural?
• Will AMESA EBITDA/EBIT recover in FY27?
• Management response
• Middle East crisis not the driver for the quarter.
• Underlying growth: B&C momentum in AMESA/India + Oral Care recovery.
• CFO attributes margin softness to one-offs:
  • “CEO transition-related costs” (two CEO costs)
  • Prior-year base effects (“phasing one-off reversal”).
• Management expects AMESA/India to be “very optimistic” for FY27.
• Notable signals
• Clear one-off explanation; less evasive than other areas.

Theme C: Beauty & Cosmetics mix vs margin “kicker” (why margins didn’t jump more)

• Core questions
• If B&C is growing faster, why didn’t margins expand more sharply?
• Concern about EBITDA vs EBIT optics (depreciation/currency effects).
• Management response
• Margin benchmark should be full-year vs full-year.
• Full-year EBITDA margin expanded from ~19.9% to 20.4% (+50 bps).
• Investments in B&C are ongoing; “expansion is gradual” due to growth resourcing.
• EBIT also expanded: “EBIT has moved from 11.8% to 12.3%”.
• Notable signals
• Management concedes the “kicker” is not immediate and reframes it as investment-led gradual expansion.

Theme D: Guidance credibility and inflation vs 11%–13% growth range

• Core questions
• With RM inflation assumptions, why guide only 11%–13% (could be mid-teens)?
• How does Thailand ramp-up affect guidance?
• Management response
• Guidance is long-term; quarterly variations possible.
• Middle East inflation is “temporary” and not included in steady-state guidance.
• Reiterates: “low double-digit growth” and EBITDA growth slightly ahead.
• Notable signals
• Guidance is defended as steady-state; however, inflation quantification is repeatedly deferred.

Theme E: Capex, Thailand ramp, depreciation, and dividend timing

• Core questions
• Capex breakdown (INR ~480 cr) vs depreciation; is capex signaling inorganic activity?
• Why no dividend? When will merger complete and dividend resume?
• Thailand plant capacity utilization and when volumes contribute.
• Management response
• Capex largely driven by B&C investments; capex may be temporarily above depreciation but will be phased.
• Dividend: merger mechanics—“both the companies cannot declare dividend till the merger is completed”.
• Merger timeline: expected around Q4 FY27 (with caveat approvals not fully in their control).
• Thailand volumes: plant set up in November; “no significant volume… in these numbers”; volumes start in next couple of quarters and scale gradually.
• Notable signals
• Thailand contribution timing is pushed out (explicitly “unrealistic” to expect high volume in the just-ended quarter).

Theme F: Merger details—Indovida margins, customer overlap, and information constraints

• Core questions
• Indovida operating margin and whether EPL can maintain margins post-merger.
• Customer overlap and whether revalidation/onboarding approvals are needed.
• Beverages category performance (since Indovida has beverages exposure).
• Management response
• Margin accretive claim; but no detailed Indovida margin walk-through due to regulatory/information constraints.
• Customer overlap acknowledged (Unilever, L’Oréal, P&G), but management claims customers welcomed the deal.
• Beverages: management states they have no knowledge and cannot comment until merger completion.
• Notable signals
• Strong deflection on Indovida-specific operational details (partly regulatory, but still limits investor visibility).

4. Guidance / Outlook

Explicit guidance (quantitative)

• Revenue growth (long-term): 11% to 13% low double-digit growth range.
• EBITDA growth: “slightly ahead of revenue growth”.
• Margins: EBITDA margin sustained above 20% (current run-rate), with “margin discipline” and gradual improvement.
• Tax rate (steady state): “18% to 22%” (management expects ~18% this year, lower end).

Implicit signals (qualitative)

• Middle East crisis: management expects full cost recovery with no lag (suggests margin optics may fluctuate but absolute EBITDA growth should remain robust).
• Thailand ramp: volumes expected to start contributing “in the next couple of quarters” and scale gradually; near-term volume contribution is limited.
• B&C momentum: management sees “strong headroom” to sustain robust B&C growth trajectory.
• Capex posture: capex may remain slightly elevated vs depreciation in FY27 due to growth opportunities.

5. Standout Statements (direct quotes where useful)

• Merger framing
• “This is a landmark quarter… proposed merger with Indovida, a transformational move”
• “nearly $1 billion consumer packaging platform… margin and value accretive”
• Operating momentum
• “Revenue for the quarter grew by 17.6%… margins sustained above 20%”
• “highest ever revenue growth in the last 5 years”
• Middle East crisis mitigation
• “prioritizing supply security… ensuring that cost impact gets fully passed on”
• “We remain confident of delivering robust absolute EBITDA growth”
• “we don’t see… any lag” in cost recovery (including non-contractual over time)
• Thailand ramp realism
• “in these numbers, there’s not much volume from Thailand”
• “FY27, we will start seeing volumes from Thailand in the next couple of quarters”
• Guidance discipline
• “guidance is a long-term guidance… there will be quarters where… pricing—costs go up… variation…”
• Dividend constraint
• “both the companies cannot declare dividend till the merger is completed”

6. Red Flags / Positive Signals

Red flags
– Limited quantification of crisis inflation and margin “walk” (repeated “difficult to give one number”).
– Information constraints around Indovida (beverages category, operating margin details) reduce investor ability to underwrite merger synergy claims.
– Thailand contribution timing is explicitly downplayed for near-term numbers; investors may face ramp uncertainty.
– Optics vs structure: management repeatedly asks to judge margins on full-year basis—could mask quarter-to-quarter volatility.

Positive signals
– Clear, repeatable pass-through framework (“landed cost plus power pass-through”).
– Strong B&C momentum with consistent multi-quarter growth.
– Balance sheet improvement: “net debt to EBITDA… 0.52x”.
– Credible operational explanations for AMESA margin softness (CEO transition costs + base effects).

7. Historical Comparison & Consistency Analysis (vs prior calls)

a. Change in Tone Over Time

• Current call (Q4 FY26): More Optimistic
• Adds a major positive catalyst: merger announced as “transformational”.
• Still confident on crisis management, but now paired with stronger growth narrative (B&C scale + portfolio shift).
• Prior calls
• Q3 FY26 (Feb 13, 2026): optimistic but more focused on execution and Europe/AMESA variability; Thailand described as early ramp.
• Q2/H1 FY26 (Nov 12, 2025): optimistic with margin expansion and Thailand commissioning; less macro-crisis emphasis.
• Merger conference (Mar 30, 2026): very optimistic on synergies and accretion, but more “transaction” heavy than “operating” heavy.

Shift drivers
– Management now blends transaction optimism with operational proof (double-digit growth streak, 20%+ margins, deleveraging).

b. Tracking Past Commitments vs Outcomes

• B&C momentum / “headroom”
• Prior: repeated “B&C pivot working” and “headroom”.
• Current: delivers “record 30%” quarter growth and “fourth consecutive quarter of over 20% growth”.
• ✅ Delivered
• Thailand ramp
• Prior (Q2 FY26): Thailand plant started operations in Oct; “start contributing in Q3”.
• Current: admits “not much volume from Thailand” in Q4; volumes expected next couple of quarters; scale gradually.
• ⏳ Delayed / pushed out
• Margin recovery / Europe initiatives
• Prior (Q3 FY26): Europe margin issues expected to improve; mid-teen target.
• Current: Europe growth “robust” at 15.5% in Q4, but no explicit Europe margin commentary in opening remarks beyond “within guided operating range”.
• ⏳ Partially tracked (less clarity on whether Europe is fully back to mid-teens consistently)

c. Narrative Shifts

• Portfolio emphasis strengthened
• Earlier: B&C pivot as a strategy.
• Now: B&C is described as larger than Oral Care in most key markets, and mix is “more balanced and diversified”.
• Macro risk framing evolves
• Earlier calls: tariff/macro discussed generally.
• Now: Middle East crisis is explicitly operationalized with pass-through mechanics and supply coverage timelines.
• Merger narrative dominates
• Current call adds a new “center of gravity” around Indovida integration, while still maintaining B&C execution.

d. Consistency & Credibility Signals

• Medium credibility
• Strength: consistent long-term guidance stance (11%–13% revenue; EBITDA ahead) and consistent B&C execution proof.
• Weakness: recurring deferrals/qualifiers on:
  • crisis inflation quantification,
  • Indovida-specific operational details,
  • Thailand ramp contribution timing.
• No clear pattern of outright contradiction, but underwriting details are often withheld.

e. Evolution of Key Themes

• Demand / growth: Improving/stable—double-digit growth streak continues.
• Margins: Stable around 20%+; management claims gradual expansion, but quarter optics vary.
• Expansion: B&C-led organic expansion + Thailand ramp; merger adds rigid packaging expansion into emerging markets.
• Regulatory/macro risk: becomes more concrete (Middle East crisis pass-through + supply security).

f. Additional Insights (cross-period intelligence)

• The company’s “no lag” cost recovery stance is increasingly emphasized, likely because investors are comparing to the earlier 2023–24 margin recovery cycle (explicitly referenced by an analyst). Management is proactively trying to pre-empt margin skepticism.
• Thailand ramp has shifted from “commercial billing / start contributing” language (earlier) to “volumes not significant yet” (current), suggesting ramp timing risk is real even if long-term intent remains unchanged.